Abstract
The chromosomal region 10q23-24 is frequently deleted in a number of tumour types, including prostate adenocarcinoma and glioma. A candidate tumour-suppressor gene at 10q23.3, designated PTENor MMAC1, with putative actin-binding and tyrosine phosphatase domains has recently been described. Mutations in PTEN have been identified in cell lines derived from gliomas, melanomas and prostate tumours and from a number of tumour specimens derived from glial, breast, endometrial and kidney tissue. Germline mutations in PTEN appear to be responsible for Cowden disease. We identified five PTEN mutations in 37 primary prostatic tumours analysed and found that 70% of tumours showed loss or alteration of at least one PTEN allele, supporting the evidence for PTEN involvement in prostate tumour progression. We raised antisera to a peptide from PTEN and showed that reactivity occurs in numerous small cytoplasmic organelles and that the protein is commonly expressed in a variety of cell types. Northern blot analysis revealed multiple RNA species; some arise as a result of alternative polyadenylation sites, but others may be due to alternative splicing.
MeSH Terms
Amino Acid Sequence
Blotting, Northern
DNA Mutational Analysis
DNA, Neoplasm/genetics
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Humans
Male
Molecular Sequence Data
PTEN Phosphohydrolase
Phosphoric Monoester Hydrolases/genetics
Prostatic Neoplasms/genetics
RNA, Neoplasm/analysis
Tumor Suppressor Proteins
Chemicals
DNA, Neoplasm
RNA, Neoplasm
Tumor Suppressor Proteins
Phosphoric Monoester Hydrolases
PTEN Phosphohydrolase
PTEN protein, human
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Gray I C
Imperial Cancer Research Technology, Applied Development Laboratory, St Bartholomew's Hospital, London, UK.
Stewart L M
Phillips S M
Hamilton J A
Gray N E
Watson G J
Spurr N K
Snary D
References (11)
11 references, click to expand
-
Subcellular separation and molecular nature of human histocompatibility antigens (HL-A).
Nature. 1974 Feb 15;247(5441):457-61
PMID: 4131934
-
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.
Science. 1997 Mar 28;275(5308):1943-7
PMID: 9072974
-
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.
Cancer Res. 1997 Jun 1;57(11):2124-9
PMID: 9187108
-
Germline mutations in PTEN are present in Bannayan-Zonana syndrome.
Nat Genet. 1997 Aug;16(4):333-4
PMID: 9241266
-
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Cancer Res. 1997 Sep 1;57(17):3657-9
PMID: 9288766
-
Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.
Oncogene. 1998 Jan 8;16(1):89-93
PMID: 9467947
-
Somatic mutations of PTEN in glioblastoma multiforme.
Cancer Res. 1997 Oct 1;57(19):4183-6
PMID: 9331071
-
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.
Cancer Res. 1997 Nov 15;57(22):4997-5000
PMID: 9371490
-
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Cancer Res. 1997 Dec 1;57(23):5221-5
PMID: 9393738
-
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Cancer Res. 1998 Jan 15;58(2):204-9
PMID: 9443392
-
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.
Cancer Res. 1997 Sep 15;57(18):3935-40
PMID: 9307275